The main factors affecting the clinical effect estimates were the sources of evidence for overall survival, and the assumptions made in the extrapolation of the benefit in a lifetime horizon. [...] When this modification is made, the extra cost and effect of nivolumab is $123,608 and 0.861 QALYs, resulting in an increase in the ICER to $143,564/QALY • In addition to the assumption above, the EGP assumed treatment discontinuation for ipilimumab will follow the same pattern as in the Checkmate-067[1], where patients could be discontinuing treatment with ipilimumab before they reach the full 4 [...] When this modification is made, the extra cost and effect of nivolumab is $103,186 and 0.603 QALYs with an ICER of $171,189/QALY • A combination of the reduced time horizon and the assumption of a log-logistic distribution for the extrapolation of overall survival was made by the EGP. [...] When this modification is made, the extra cost and effect of nivolumab is $125,670 and 0.893 QALYs with an ICER of $140,756/QALY • Note that due to the structure of the model submitted, a change in the time to treatment discontinuation has an effect on both the estimates of incremental costs and QALYs gained. [...] When both modifications were made, the extra cost and effect of nivolumab was $111,725 and 0.841 QALYs resulting in an ICER of $132,809/QALY • A combination of the reduced time horizon and the assumption of treatment discontinuation probability that follows the same trend as that of CheckMate 066[4] was made by the EGP.
- Pages
- 20
- Published in
- Toronto, ON, CA